You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
Title |
Evaluation of Dimebon in cellular model of Huntington's disease
|
---|---|
Published in |
Molecular Neurodegeneration, October 2008
|
DOI | 10.1186/1750-1326-3-15 |
Pubmed ID | |
Authors |
Jun Wu, Qin Li, Ilya Bezprozvanny |
Abstract |
Dimebon is an antihistamine compound with a long history of clinical use in Russia. Recently, Dimebon has been proposed to be useful for treating neurodegenerative disorders. It has demonstrated efficacy in phase II Alzheimer's disease (AD) and Huntington's disease (HD) clinical trials. The mechanisms responsible for the beneficial actions of Dimebon in AD and HD remain unclear. It has been suggested that Dimebon may act by blocking NMDA receptors or voltage-gated Ca2+ channels and by preventing mitochondrial permeability pore transition. |
Mendeley readers
The data shown below were compiled from readership statistics for 69 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 2 | 3% |
United Kingdom | 1 | 1% |
Unknown | 66 | 96% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 24 | 35% |
Student > Ph. D. Student | 12 | 17% |
Student > Doctoral Student | 6 | 9% |
Professor > Associate Professor | 5 | 7% |
Student > Bachelor | 3 | 4% |
Other | 12 | 17% |
Unknown | 7 | 10% |
Readers by discipline | Count | As % |
---|---|---|
Agricultural and Biological Sciences | 22 | 32% |
Medicine and Dentistry | 12 | 17% |
Neuroscience | 7 | 10% |
Chemistry | 6 | 9% |
Pharmacology, Toxicology and Pharmaceutical Science | 3 | 4% |
Other | 9 | 13% |
Unknown | 10 | 14% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 October 2020.
All research outputs
#4,696,396
of 22,787,797 outputs
Outputs from Molecular Neurodegeneration
#532
of 847 outputs
Outputs of similar age
#17,328
of 91,145 outputs
Outputs of similar age from Molecular Neurodegeneration
#1
of 2 outputs
Altmetric has tracked 22,787,797 research outputs across all sources so far. Compared to these this one has done well and is in the 76th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 847 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 14.2. This one is in the 36th percentile – i.e., 36% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 91,145 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.
We're also able to compare this research output to 2 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them